Cyclic 21/7 Dosing and the Withdrawal Bleed
Placebo week triggers a scheduled hormone drop and bleed.
- 21: Active pill days (per standard pack)
- 7: Placebo days (hormone-free interval)
- ~13: Bleeds per year (cyclic regimen)
- Withdrawal: Bleed type (not a true period)
Why the classic pack causes monthly bleeding
Placeholder: hormone withdrawal during placebo days sheds the lining.
Continuous Dosing and Flat Hormone Levels
Daily active pills keep circulating hormone levels steady.
- 365: Active pill days (continuous regimen)
- 0: Placebo days (no scheduled break)
- Low: Hormone variability (flat serum profile)
- Extended-cycle: Common brands (e.g. 84/7 or 365-day)
How continuous dosing flattens the hormone curve
Placeholder: uninterrupted dosing avoids the cyclic hormone dip.
Removing the Hormone-Free Interval
Skipping placebo days prevents the drop that triggers bleeding.
- 0 days: HFI length (vs 7 in cyclic use)
- Sustained: Ovulation suppression (no rebound window)
- Minimal: Follicular activity (reduced escape risk)
- Higher: Adherence benefit (fewer missed-pill risks)
Clinical rationale for eliminating the pill-free week
Placeholder: the 7-day gap was historical, not medically required.
Endometrial Suppression Under Continuous Use
Lining stays thin and inactive without cyclic buildup and shed.
- Thin: Endometrial thickness (atrophic pattern)
- ~70-80%: Amenorrhea by month 12 (approximate placeholder)
- Reduced: Lining turnover (less proliferation)
- Full: Reversibility (after stopping)
Why suppression is considered safe long-term
Placeholder: thin quiescent lining does not require monthly shedding.
Managing Breakthrough Bleeding on Continuous Regimens
Unscheduled spotting is common early and typically declines.
- Months 1-3: Peak spotting window (placeholder estimate)
- Marked: Decline by month 6 (placeholder estimate)
- Short break: Common fix (3-4 day pause if needed)
- Minority: Discontinuation cause (bleeding-related)
Practical strategies for breakthrough bleeding
Placeholder: brief pill-free pauses can resolve persistent spotting.
Placeholder: consult a clinician before adjusting any regimen.